ホーム › 多発性骨髄腫 › メリーランド州 › Baltimore
Baltimore、MDにおける多発性骨髄腫の臨床試験
Baltimoreとその周辺地域（約30マイル以内）の拠点で、多発性骨髄腫に関する13件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第3相
- Johns Hopkins Hospital, Baltimore
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第3相
- University of Maryland School of Medicine, Baltimore
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
被験者募集中第3相
- Johns Hopkins University School of Medicine JHUSOM, Baltimore
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
被験者募集中早期第1相
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
被験者募集中第3相
- Johns Hopkins Asthma & Allergy Center, Baltimore
Collection of Tissue Samples for Cancer Research
被験者募集中観察研究
- Johns Hopkins University, Baltimore
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
被験者募集中第3相
- University of Maryland | Greenebaum Cancer Center, Baltimore
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
被験者募集中第3相
- Research Site, Baltimore
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
被験者募集中第1相
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
被験者募集中第3相
- Greater Baltimore Medical Center, Baltimore
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
被験者募集中第3相
- Greenebaum Cancer Center UM of MD, Baltimore
- John Hopkins, Baltimore
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
被験者募集中第1/2相
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1/2相
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
他の都市における多発性骨髄腫の試験
- New York City, NY60件の研究
- Boston, MA42件の研究
- Atlanta, GA41件の研究
- Houston, TX38件の研究
- Durham, NC37件の研究
- Nashville, TN32件の研究
- Denver, CO27件の研究
- Rochester, MN24件の研究
- St. Louis, MO24件の研究
- Columbus, OH24件の研究
- Baldwin Park, CA23件の研究
- Chicago, IL22件の研究
Baltimoreにおける他の研究
- 非小細胞肺癌60件の研究
- 乳がん47件の研究
- 前立腺がん43件の研究
- 肺がん40件の研究
- がん（全種類）37件の研究
- 大腸癌31件の研究
- 膵臓がん31件の研究
- 転移性癌28件の研究
- 肥満症25件の研究
- 心不全24件の研究
- 膀胱癌24件の研究
- 脳卒中22件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。